EP
ALNY icon

Edgestream Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Edgestream Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,810
Closed -$1.92M – 950
2026
Q1 		$1.92M Sell
5,810
-1,438
-20% -$489K 0.06% 500
2025
Q4 		$2.88M Buy
+7,248
New +$3.21M 0.08% 438
2025
Q1 		– Sell
-13,806
Closed -$3.25M – 826
2024
Q4 		$3.25M Buy
+13,806
New +$3.63M 0.14% 291
2024
Q3 		– Sell
-6,052
Closed -$1.47M – 824
2024
Q2 		$1.47M Sell
6,052
-17,303
-74% -$2.73M 0.07% 426
2024
Q1 		$3.49M Buy
23,355
+15,394
+193% +$2.57M 0.17% 198
2023
Q4 		$1.52M Buy
7,961
+5,536
+228% +$943K 0.11% 309
2023
Q3 		$429K Sell
2,425
-9,120
-79% -$1.74M 0.03% 628
2023
Q2 		$2.19M Buy
11,545
+3,872
+50% +$768K 0.2% 159
2023
Q1 		$1.54M Buy
+7,673
New +$1.61M 0.17% 197
2022
Q3 		– Sell
-10,785
Closed -$1.57M – 443
2022
Q2 		$1.57M Buy
10,785
+6,783
+169% +$962K 0.12% 248
2022
Q1 		$653K Sell
4,002
-17,985
-82% -$2.74M 0.05% 383
2021
Q4 		$3.73M Buy
21,987
+5,566
+34% +$1.03M 0.23% 136
2021
Q3 		$3.1M Buy
16,421
+4,740
+41% +$889K 0.19% 182
2021
Q2 		$1.98M Buy
+11,681
New +$1.71M 0.12% 221

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Edgestream Partners's ALNY Position: Q2 2026 in Review

Edgestream Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 5,810 shares — an estimated $1.92M sold.

Edgestream Partners first reported a position in ALNY in Q2 2021 and held it in 14 quarters. The position peaked at $3.73M in Q4 2021. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Edgestream Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Edgestream Partners sold 5,810 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.92M.
  • Edgestream Partners first reported a position in Alnylam Pharmaceuticals in Q2 2021 and held it in 14 quarters.
  • Edgestream Partners's Alnylam Pharmaceuticals position peaked at $3.73M in Q4 2021.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.